|Bid||254.50 x 800|
|Ask||254.95 x 900|
|Day's Range||243.01 - 247.63|
|52 Week Range||198.64 - 258.45|
|Beta (5Y Monthly)||0.59|
|PE Ratio (TTM)||26.31|
|Earnings Date||Apr 25, 2022 - Apr 29, 2022|
|Forward Dividend & Yield||7.76 (3.19%)|
|Ex-Dividend Date||May 16, 2022|
|1y Target Est||249.25|
Mirati is unlikely to carve out a share of the lung cancer market, analysts said Friday as MRTX stock collapsed on a testing disappointment.
Mirati (MRTX) posts positive data from a phase II study evaluating its lung cancer candidate adagrasib. However, the drug caused side-effects in a large number of study participants.
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.